Wearable Robotics, an Italian firm specializing in rehabilitation technology, has raised €5 million in a Series A funding round to enhance international expansion and extend its product range. Emerging from the Sant’Anna School of Advanced Studies in Pisa, the company received funding primarily from CDP Venture Capital via its Accelerators Fund. Investors include MITO Technology, LIFTT, SIMEST, RoboIT, and Toscana Next, managed by CDP Venture Capital and supported by key Tuscan banking foundations. Lucia Lencioni is the CEO.
Founded in 2014, Wearable Robotics designs wearable robotic rehabilitation devices enhanced with augmented and virtual reality for neuromotor recovery. Their flagship product, the ALEX RS, is a bilateral upper-limb exoskeleton for post-stroke rehabilitation, offering coverage of 92% of the human arm’s natural motion range. CE certified as a Class IIa medical device, over 50 units have been implemented in clinics and rehabilitation centers across 20 countries.
The company holds eight proprietary patents related to kinematics, sensors, actuation systems, and exoskeleton design, operating its biomedical division under Nexum Robotics. With SIMEST’s involvement, financed by the Italian Ministry of Foreign Affairs, North America emerges as a focal expansion region.
The investment group, showcasing CDP Venture Capital’s startup infrastructure, LIFTT’s deep tech expertise, and RoboIT’s robotics technology transfer mission, highlights a unified Italian public-private effort to support a robust European rehabilitation robotics entity.
The €5 million funding aims to finalize the product lineup, secure new market regulatory approvals, expand commercial and distribution networks, and optimize production capabilities. With an estimated 200 million global patients needing neuromotor rehabilitation post-stroke, brain injuries, or spinal cord injuries, Wearable Robotics notes that traditional therapy fully restores mobility in only about 10% of cases. Their robotic rehabilitation systems aim to close this gap through intensive, measurable, and personalized treatment.